These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Fenn KM; Kalinsky K Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574 [TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan. Dong W; Shi J; Yuan T; Qi B; Yu J; Dai J; He L Eur J Med Chem; 2019 Apr; 167():583-593. PubMed ID: 30822636 [TBL] [Abstract][Full Text] [Related]
14. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Faltas B; Goldenberg DM; Ocean AJ; Govindan SV; Wilhelm F; Sharkey RM; Hajdenberg J; Hodes G; Nanus DM; Tagawa ST Clin Genitourin Cancer; 2016 Feb; 14(1):e75-9. PubMed ID: 26541586 [TBL] [Abstract][Full Text] [Related]
15. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? Zangardi ML; Spring LM; Nagayama A; Bardia A Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322 [TBL] [Abstract][Full Text] [Related]
16. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624 [TBL] [Abstract][Full Text] [Related]
17. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. Furlanetto J; Marmé F; Loibl S Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628 [TBL] [Abstract][Full Text] [Related]
19. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Gray JE; Heist RS; Starodub AN; Camidge DR; Kio EA; Masters GA; Purcell WT; Guarino MJ; Misleh J; Schneider CJ; Schneider BJ; Ocean A; Johnson T; Gandhi L; Kalinsky K; Scheff R; Messersmith WA; Govindan SV; Maliakal PP; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM Clin Cancer Res; 2017 Oct; 23(19):5711-5719. PubMed ID: 28679770 [No Abstract] [Full Text] [Related]
20. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Mathew Thomas V; Tripathi N; Agarwal N; Swami U Expert Rev Anticancer Ther; 2022 Apr; 22(4):335-341. PubMed ID: 35249433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]